Entia Biosciences, Inc. 4

4 · Entia Biosciences, Inc. · Filed Jun 13, 2013

Form 4

Period: 2013-06-11

Director

Transactions

Purchase
Convertible Promissory Note
2013-06-11$40000.00/sh+1$40,000→ 25,000 total
Exercise: $5.00From: 2013-06-11Exp: 2013-12-31→ Series A Preferred Stock (8,000 underlying)
Purchase
Common Stock Purchase Warrants
2013-06-11$0.45/sh+10,000$4,500→ 10,000 total
Exercise: $0.45From: 2013-07-01Exp: 2018-06-10→ Common Stock (10,000 underlying)
Purchase
Series A Preferred Stock
2013-06-11$5.00/sh+11,338$56,690→ 19,338 total(indirect: By Trust)
Exercise: $0.50From: 2013-06-11→ Common Stock (113,380 underlying)

Footnotes (3)

[F1]The conversion price is adjustable pursuant to certain anti-dilution provisions.
[F2]The preferred shares are convertible into common shares at any time, but under certain circumstances there could be a mandatory conversion, as for example after the anniversary of the effectiveness of a registration statement covering the common stock underlying the preferred shares or within 30 days of the closing of a private placement exceeding $5 million.
[F3]These shares of Series A preferred stock are being issued pursuant to the conversion of principal and accrued interest on a promissory note held by Dr. Sobol.

Documents

1 file